

SUPPLEMENTAL TABLE

Platelet extracellular vesicles as biomarkers for arterial thrombosis.

Aleksandra Gąsecka^{1,2}, Anita N. Böing², Krzysztof J. Filipiak¹, Rienk Nieuwland²

¹ 1st Chair and Department of Cardiology, Medical University of Warsaw, Warsaw, Poland

² Laboratory of Experimental Clinical Chemistry, and Vesicle Observation Centre, Academic Medical Centre of the University of Amsterdam, Amsterdam, The Netherlands

Table 3. Reported concentrations of platelet extracellular vesicles (PEV) detected with flow cytometry in acute coronary syndrome, diabetes mellitus and autoimmune disease over the last two decades. Data are presented as mean ± standard deviation (SD) or as median (range).

CD: cluster of differentiation; NS: not significant; n.s.: not stated.

Clinical condition	Year	PEV phenotype	Number of participants		PEV concentration x 10 ⁷ /L		P	Ref.
			Patients	Controls	Patients	Controls		
Acute coronary syndrome	2014	CD41	51	50	1750 ± 1630	1430 ± 620	NS	[36]
	2013	CD42b	50	40	240 (120 – 4860)	360 (180 – 4410)	NS	[37]
	2007	CD41	70	24	39 (11 – 68)	32 (24 – 52)	NS	[38]
	1997	CD61	21		1 ± 2		<0.01	[39]
Diabetes mellitus	2014	CD61	10	20	610 ± n.s.	170 ± n.s.	<0.01	[41]
	2010	CD31/CD42	63	29	480 (360 – 550)	290 (230 – 350)	<0.001	[42]
	2002	CD41	24	19	98 ± 14	56 ± 34	<0.05	[43]
Auto-immune disease	2011	CD31/CD41	52	30	450 ± 390	560 ± 700	NS	[44]
	2006	CD61	30	20	90 ± 10	50 ± 7	0.009	[45]
	2002	CD61	19	10	60 (12–2240)	10 (4–190)	0.005	[46]